<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180722040556N13</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-11-15</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Prevention of Cardiotoxicity Induced by Taxane and Trastuzumab Therapy</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the Efficacy of Sacubitril/Valsartan Compared with Enalapril in the Prevention of Cardiotoxicity Induced by Taxane and Trastuzumab Therapy in Patients with HER۲-Positive Breast Cancer: A Randomized Controlled Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>86</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/94189</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Sample randomization will be performed using the block randomization method. The randomization process involves entering information such as the number of treatment groups, block size (a multiple of the number of treatment groups), and total sample size into an online randomization tool [1]. Based on the allocation codes generated by the software, the treatment assignment for each patient will be determined.

In this study, since there are two treatment groups, blocks of four (a multiple of two) will be used. The anticipated sample of eligible patients will be randomly allocated to one of two groups: the sacubitril/valsartan group or the enalapril group.

Specifically, patients will be assigned a unique identification code in the order in which they are enrolled in the study, provided they meet the inclusion criteria. Each patient will then be allocated to either the sacubitril/valsartan or enalapril treatment group according to the allocation sequence generated by the randomization software for the corresponding code, Blinding description: To ensure blinding of the study, the clinical pharmacy specialist will generate the randomization codes using the designated online software and inform the clinical pharmacy assistant which medication should be dispensed to each patient according to their assigned code. The study medications will then be prepared by the research team, and each patient will receive a three-month supply of the assigned medication at the beginning of the study, based on their allocated code.

Throughout the three-month study period, patients will remain under the supervision of the oncologist at Seyed Al-Shohada Hospital. The clinical pharmacy assistant will monitor the patients to ensure adherence to the prescribed medication regimen in accordance with the study protocol.

Patients attending the relevant clinics will be screened by the research team for eligibility. Those who meet the inclusion criteria will be assigned a code according to the randomization sequence and will receive their medication from the clinical pharmacy assistant.

The physician responsible for performing baseline and three-month follow-up echocardiography (the study physician) will remain blinded to both the patients’ assigned codes and the medications they receive. Echocardiographic images and data will be provided to the echocardiography analyst without any information regarding the medication received by the patient. Each patient’s echocardiographic records will be identified solely by a randomly assigned code to maintain blinding during image analysis.</study_design>
      <phase>3</phase>
      <hc_freetext>Breast cancer patients.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The intervention will involve identifying patients with HER2-positive breast cancer who are scheduled to receive a taxane-containing chemotherapy regimen consisting of either paclitaxel (80 mg/m² IV weekly) or docetaxel (75–100 mg/m² IV every three weeks), in combination with trastuzumab (typically 6 mg/kg every three weeks). Eligible patients will have no pre-existing heart failure but will be at increased risk of developing heart failure due to exposure to potentially cardiotoxic anticancer therapies. Patients will be identified by the investigator, and informed consent will be obtained prior to enrollment.Patients will receive sacubitril/valsartan at a dose of 50 mg daily for a minimum of three months. The primary objective of this intervention is to evaluate the potential cardioprotective effects of sacubitril/valsartan in reducing cardiac complications associated with cancer treatment.Following patient identification and obtaining written informed consent, treatment allocation will be performed randomly, and patients will be blinded to their assigned treatment to minimize potential bias in the study outcomes. Medication adherence will be carefully assessed throughout the study. Patients with medication adherence below 80% will be withdrawn from the study to ensure the validity and reliability of the final data. Furthermore, adverse events and clinical changes will be regularly monitored throughout the study period. Intervention 2: Control group: Patients with HER2-positive breast cancer who are scheduled to receive a taxane-containing chemotherapy regimen consisting of either paclitaxel (80 mg/m² IV weekly) or docetaxel (75–100 mg/m² IV every three weeks), in combination with trastuzumab (typically 6 mg/kg every three weeks), will be identified by the investigator. Eligible patients must have no pre-existing heart failure but will be considered at increased risk of developing heart failure due to exposure to potentially cardiotoxic anticancer therapies. Written informed consent will be obtained from all eligible patients prior to enrollment.Patients will receive enalapril at a dose of 5 mg daily for a minimum of three months. The primary objective of this intervention is to evaluate the cardioprotective effects of enalapril in reducing cardiac complications associated with cancer treatment.Following patient identification and obtaining informed consent, treatment allocation will be performed randomly, with patients blinded to their assigned treatment to minimize potential bias in study outcomes. Medication adherence will be carefully assessed throughout the study. Patients with medication adherence below 80% will be withdrawn from the study to maintain the validity and reliability of the final data. Furthermore, adverse events and clinical changes will be regularly monitored throughout the study period.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All collected data

When:
From May 2027

To whom:
All academic centers

Conditions:
All documents with citation

Where to obtain:
Email address

How to obtain:
After sending a request, we will call the related person and the data will be revealed in less than one week.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Azadeh Moghaddas</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezarjerib</address>
        <city>Esfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673461</zip>
        <telephone>+98 31 1792 7074</telephone>
        <email>moghaddas@pharm.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Azadeh Moghaddas</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezarjerib</address>
        <city>Esfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673461</zip>
        <telephone>+98 31 1792 7074</telephone>
        <email>moghaddas@pharm.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Adult patients with newly diagnosed HER2-positive breast cancer who have not previously received any taxane- and trastuzumab-containing chemotherapy regimen.
2. Patients scheduled to receive a taxane-based chemotherapy regimen consisting of either paclitaxel 80 mg/m² IV weekly or docetaxel 75–100 mg/m² IV every three weeks, in combination with trastuzumab (typically 6 mg/kg IV every three weeks).
3. Patients must have a baseline left ventricular ejection fraction (LVEF) of ≥ 50% at study enrollment
4. Patients must have no history of cardiovascular diseases, including heart failure, angina, or hypertension.
5. Patients must provide informed consent to participate in the study and agree to comply with the study protocol, including a minimum follow-up period of three months.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>1. Patients with a systolic blood pressure of less than 100 mmHg.
2. Patients with contraindications to angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), or neprilysin inhibitors.
3. Patients who develop potential adverse effects or hypersensitivity reactions to sacubitril/valsartan or enalapril during the course of treatment.
4. Patients with renal impairment, defined as an estimated glomerular filtration rate (eGFR) of less than 45 mL/min/1.73 m².
5. Patients with a serum potassium level greater than 5 mmol/L.
6. Patients who have experienced adverse effects, such as angioedema or cough, following the use of enalapril or other ACEIs.
7. Patients who develop another serious medical condition during the intervention period that necessitates treatment with medications affecting the cardiovascular system.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>C50</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Malignant neoplasm of breast</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The intervention will involve identifying patients with HER2-positive breast cancer who are scheduled to receive a taxane-containing chemotherapy regimen consisting of either paclitaxel (80 mg/m² IV weekly) or docetaxel (75–100 mg/m² IV every three weeks), in combination with trastuzumab (typically 6 mg/kg every three weeks). Eligible patients will have no pre-existing heart failure but will be at increased risk of developing heart failure due to exposure to potentially cardiotoxic anticancer therapies. Patients will be identified by the investigator, and informed consent will be obtained prior to enrollment.Patients will receive sacubitril/valsartan at a dose of 50 mg daily for a minimum of three months. The primary objective of this intervention is to evaluate the potential cardioprotective effects of sacubitril/valsartan in reducing cardiac complications associated with cancer treatment.Following patient identification and obtaining written informed consent, treatment allocation will be performed randomly, and patients will be blinded to their assigned treatment to minimize potential bias in the study outcomes. Medication adherence will be carefully assessed throughout the study. Patients with medication adherence below 80% will be withdrawn from the study to ensure the validity and reliability of the final data. Furthermore, adverse events and clinical changes will be regularly monitored throughout the study period.</i_keyword>
      <i_keyword>Control group: Patients with HER2-positive breast cancer who are scheduled to receive a taxane-containing chemotherapy regimen consisting of either paclitaxel (80 mg/m² IV weekly) or docetaxel (75–100 mg/m² IV every three weeks), in combination with trastuzumab (typically 6 mg/kg every three weeks), will be identified by the investigator. Eligible patients must have no pre-existing heart failure but will be considered at increased risk of developing heart failure due to exposure to potentially cardiotoxic anticancer therapies. Written informed consent will be obtained from all eligible patients prior to enrollment.Patients will receive enalapril at a dose of 5 mg daily for a minimum of three months. The primary objective of this intervention is to evaluate the cardioprotective effects of enalapril in reducing cardiac complications associated with cancer treatment.Following patient identification and obtaining informed consent, treatment allocation will be performed randomly, with patients blinded to their assigned treatment to minimize potential bias in study outcomes. Medication adherence will be carefully assessed throughout the study. Patients with medication adherence below 80% will be withdrawn from the study to maintain the validity and reliability of the final data. Furthermore, adverse events and clinical changes will be regularly monitored throughout the study period.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The extent of changes in left ventricular systolic function before and after the intervention. Timepoint: Before the intervention began and after three months of taking either enalapril or sacubitril/valsartan. Method of measurement: Examination of echocardiographic indices including GLS and assessment of cardiac troponin enzyme.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-10-14</approval_date>
        <contact_name>Ethics committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>Faculty of Pharmacy, Isfahan University of medical Sciences, Hezar jarib street, Isfahan, Iran Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
